Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bio-Techne Corporation    TECH

BIO-TECHNE CORPORATION

(TECH)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
304.9(c) 303.74(c) 302.82(c) 301.75(c) 297.65(c) Last
158 315 134 727 139 416 170 741 69 554 Volume
+0.87% -0.38% -0.30% -0.35% -1.36% Change
More quotes
Financials (USD)
Sales 2021 839 M - -
Net income 2021 142 M - -
Net cash position 2021 173 M - -
P/E ratio 2021 83,5x
Yield 2021 0,43%
Sales 2022 944 M - -
Net income 2022 180 M - -
Net cash position 2022 176 M - -
P/E ratio 2022 66,4x
Yield 2022 0,45%
Capitalization 11 492 M 11 492 M -
EV / Sales 2021 13,5x
EV / Sales 2022 12,0x
Nbr of Employees 2 300
Free-Float 99,4%
More Financials
Company
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The... 
More about the company
All news about BIO-TECHNE CORPORATION
11/25BIO TECHNE : Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitat..
PR
11/13BIO-TECHNE CORPORATION : Ex-dividend day for
FA
11/11BIO TECHNE : To Present At The Stephens Annual Investment Conference 2020
PR
11/09BIO TECHNE : Xbrl q1 2021
PU
11/09BIO TECHNE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL (form 10-Q)
AQ
11/05BIO-TECHNE CORP : Results of Operations and Financial Condition, Other Events, F..
AQ
11/05BIO TECHNE : Releases First Quarter Fiscal 2021 Results
PR
11/05BIO TECHNE : Declares Dividend
PR
11/04BIO TECHNE : To Present At The Stifel 2020 Virtual Healthcare Conference
PR
11/03BIO-TECHNE CORP : Change in Directors or Principal Officers, Submission of Matte..
AQ
11/02BIO TECHNE : To Present At The 29th Annual Credit Suisse Virtual Healthcare Conf..
PR
10/29BIO-TECHNE CORPORATION : quaterly earnings release
10/28BIO TECHNE : EKF and Kantaro Partner to Market Quantitative COVID-19 Antibody Te..
PR
10/26BIO TECHNE : CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIn..
PR
10/19BIO TECHNE : Announces Commercial Release Of New SARS-CoV-2 Multi-Antigen Serolo..
PR
More news
News in other languages on BIO-TECHNE CORPORATION
10/29BIO-TECHNE CORPORATION : Veröffentlichung des Quartalsergebnisses
10/29BIO-TECHNE CORPORATION : publication des résultats trimestriels
2019BIO-TECHNE CORP : Veröffentlichung des Halbjahresergebnisses
2019BIO-TECHNE CORP : publication des résultats semestriels
2018BIO-TECHNE CORP : Veröffentlichung des Jahresergebnisses
More news
Chart BIO-TECHNE CORPORATION
Duration : Period :
Bio-Techne Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIO-TECHNE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 311,45 $
Last Close Price 297,65 $
Spread / Highest target 22,6%
Spread / Average Target 4,64%
Spread / Lowest Target -38,2%
EPS Revisions
Managers
NameTitle
Charles R. Kummeth President, Chief Executive Officer & Director
Robert V. Baumgartner Chairman
James T. Hippel CFO & Principal Accounting Officer
Robert Monroe Chief Medical Officer
Randolph C. Steer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIO-TECHNE CORPORATION35.60%11 492
IQVIA HOLDINGS INC.9.26%32 365
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
PRA HEALTH SCIENCES, INC.-0.14%7 120
SYNEOS HEALTH, INC.12.08%6 932
NOVAVAX, INC.2,477.89%6 427